The United Nations Secretary General convened a High-Level Panel in 2015 to find solutions to the existing incoherence between the right to healthcare and trade and intellectual property regulations. Thus, it received proposals from December 2015 to February 2016, from various organisations within civil society, groups of patients, study centres, governments and the pharmaceutical industry. All of them were to be analysed by a group of 16 people, expert on matters of trade, public health and human rights.
There were 176 proposals, and Salud por Derecho, along with many organisations that defend with us the need for an innovative medication model, wished to contribute by being part of one of them. This was our proposal. |
|
The high participation as well as the variety and quality of the contributions from each sector enriched the debate and provided for a complex and careful analysis by the group of experts. This analysis was made public at the end of the year by means of a 70-page report offering an in-depth perspective of intellectual property; investment in healthcare technologies; the innovation model in and of itself and the need to revise it; transparency in research processes, clinical trials and distribution and commercialisation; in addition to fostering new collaborative and open models.
|
MOBILISATION AND
IMPACT ON ACCESS TO R+D
High-Level United Nations Panel on Access to Medications
|
Spanish Medical Association roundtable
|
ENVI
|
TTIP leaks
|
Horizon 2020
|
UCM Access to Medication Conference
|
Access to Medicines and Innovation
|
Healthy innovation for all
|
European Alliance for responsible research and affordable medicines
|
EACH Group
|
EPHA Group on Access to Medicines
|
Global Health Policy Forum
|
Hepatitis C
|